Search

Your search keyword '"Lentz, Robert W."' showing total 28 results
Start Over Author "Lentz, Robert W."
28 results on '"Lentz, Robert W."'

3. Examination of Wnt signaling as a therapeutic target for pancreatic ductal adenocarcinoma (PDAC) using a pancreatic tumor organoid library (PTOL)

Author

Hawkins, Hayley J., primary, Yacob, Betelehem W., additional, Brown, Monica E., additional, Goldstein, Brandon R., additional, Arcaroli, John J., additional, Bagby, Stacey M., additional, Hartman, Sarah J., additional, Macbeth, Morgan, additional, Goodspeed, Andrew, additional, Danhorn, Thomas, additional, Lentz, Robert W., additional, Lieu, Christopher H., additional, Leal, Alexis D., additional, Messersmith, Wells A., additional, Dempsey, Peter J., additional, and Pitts, Todd M., additional

Published
2024
Full Text
View/download PDF

4. FIGURE 4 from Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic Microenvironment

Author

Amo-Aparicio, Jesus, primary, Dominguez, Adrian, primary, Atif, Shaikh M., primary, Dinarello, Alberto, primary, Azam, Tania, primary, Alula, Kibrom M., primary, Piper, Miles, primary, Lieu, Christopher H., primary, Lentz, Robert W., primary, Leal, Alexis D., primary, Bagby, Stacey M., primary, Messersmith, Wells A., primary, Karam, Sana D., primary, Dinarello, Charles A., primary, Pitts, Todd M., primary, and Marchetti, Carlo, primary

Published
2023
Full Text
View/download PDF

5. Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic Microenvironment

Author

Amo-Aparicio, Jesus, primary, Dominguez, Adrian, additional, Atif, Shaikh M., additional, Dinarello, Alberto, additional, Azam, Tania, additional, Alula, Kibrom M., additional, Piper, Miles, additional, Lieu, Christopher H., additional, Lentz, Robert W., additional, Leal, Alexis D., additional, Bagby, Stacey M., additional, Messersmith, Wells A., additional, Karam, Sana D., additional, Dinarello, Charles A., additional, Pitts, Todd M., additional, and Marchetti, Carlo, additional

Published
2023
Full Text
View/download PDF

6. FIGURE 1 from Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic Microenvironment

Author

Amo-Aparicio, Jesus, primary, Dominguez, Adrian, primary, Atif, Shaikh M., primary, Dinarello, Alberto, primary, Azam, Tania, primary, Alula, Kibrom M., primary, Piper, Miles, primary, Lieu, Christopher H., primary, Lentz, Robert W., primary, Leal, Alexis D., primary, Bagby, Stacey M., primary, Messersmith, Wells A., primary, Karam, Sana D., primary, Dinarello, Charles A., primary, Pitts, Todd M., primary, and Marchetti, Carlo, primary

Published
2023
Full Text
View/download PDF

7. Data from Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic Microenvironment

Author

Amo-Aparicio, Jesus, primary, Dominguez, Adrian, primary, Atif, Shaikh M., primary, Dinarello, Alberto, primary, Azam, Tania, primary, Alula, Kibrom M., primary, Piper, Miles, primary, Lieu, Christopher H., primary, Lentz, Robert W., primary, Leal, Alexis D., primary, Bagby, Stacey M., primary, Messersmith, Wells A., primary, Karam, Sana D., primary, Dinarello, Charles A., primary, Pitts, Todd M., primary, and Marchetti, Carlo, primary

Published
2023
Full Text
View/download PDF

8. FIGURE 3 from Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic Microenvironment

Author

Amo-Aparicio, Jesus, primary, Dominguez, Adrian, primary, Atif, Shaikh M., primary, Dinarello, Alberto, primary, Azam, Tania, primary, Alula, Kibrom M., primary, Piper, Miles, primary, Lieu, Christopher H., primary, Lentz, Robert W., primary, Leal, Alexis D., primary, Bagby, Stacey M., primary, Messersmith, Wells A., primary, Karam, Sana D., primary, Dinarello, Charles A., primary, Pitts, Todd M., primary, and Marchetti, Carlo, primary

Published
2023
Full Text
View/download PDF

9. FIGURE 8 from Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic Microenvironment

Author

Amo-Aparicio, Jesus, primary, Dominguez, Adrian, primary, Atif, Shaikh M., primary, Dinarello, Alberto, primary, Azam, Tania, primary, Alula, Kibrom M., primary, Piper, Miles, primary, Lieu, Christopher H., primary, Lentz, Robert W., primary, Leal, Alexis D., primary, Bagby, Stacey M., primary, Messersmith, Wells A., primary, Karam, Sana D., primary, Dinarello, Charles A., primary, Pitts, Todd M., primary, and Marchetti, Carlo, primary

Published
2023
Full Text
View/download PDF

10. FIGURE 6 from Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic Microenvironment

Author

Amo-Aparicio, Jesus, primary, Dominguez, Adrian, primary, Atif, Shaikh M., primary, Dinarello, Alberto, primary, Azam, Tania, primary, Alula, Kibrom M., primary, Piper, Miles, primary, Lieu, Christopher H., primary, Lentz, Robert W., primary, Leal, Alexis D., primary, Bagby, Stacey M., primary, Messersmith, Wells A., primary, Karam, Sana D., primary, Dinarello, Charles A., primary, Pitts, Todd M., primary, and Marchetti, Carlo, primary

Published
2023
Full Text
View/download PDF

11. FIGURE 5 from Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic Microenvironment

Author

Amo-Aparicio, Jesus, primary, Dominguez, Adrian, primary, Atif, Shaikh M., primary, Dinarello, Alberto, primary, Azam, Tania, primary, Alula, Kibrom M., primary, Piper, Miles, primary, Lieu, Christopher H., primary, Lentz, Robert W., primary, Leal, Alexis D., primary, Bagby, Stacey M., primary, Messersmith, Wells A., primary, Karam, Sana D., primary, Dinarello, Charles A., primary, Pitts, Todd M., primary, and Marchetti, Carlo, primary

Published
2023
Full Text
View/download PDF

12. Supplementary Figure S6 from Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic Microenvironment

Author

Amo-Aparicio, Jesus, primary, Dominguez, Adrian, primary, Atif, Shaikh M., primary, Dinarello, Alberto, primary, Azam, Tania, primary, Alula, Kibrom M., primary, Piper, Miles, primary, Lieu, Christopher H., primary, Lentz, Robert W., primary, Leal, Alexis D., primary, Bagby, Stacey M., primary, Messersmith, Wells A., primary, Karam, Sana D., primary, Dinarello, Charles A., primary, Pitts, Todd M., primary, and Marchetti, Carlo, primary

Published
2023
Full Text
View/download PDF

13. FIGURE 2 from Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic Microenvironment

Author

Amo-Aparicio, Jesus, primary, Dominguez, Adrian, primary, Atif, Shaikh M., primary, Dinarello, Alberto, primary, Azam, Tania, primary, Alula, Kibrom M., primary, Piper, Miles, primary, Lieu, Christopher H., primary, Lentz, Robert W., primary, Leal, Alexis D., primary, Bagby, Stacey M., primary, Messersmith, Wells A., primary, Karam, Sana D., primary, Dinarello, Charles A., primary, Pitts, Todd M., primary, and Marchetti, Carlo, primary

Published
2023
Full Text
View/download PDF

14. FIGURE 7 from Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic Microenvironment

Author

Amo-Aparicio, Jesus, primary, Dominguez, Adrian, primary, Atif, Shaikh M., primary, Dinarello, Alberto, primary, Azam, Tania, primary, Alula, Kibrom M., primary, Piper, Miles, primary, Lieu, Christopher H., primary, Lentz, Robert W., primary, Leal, Alexis D., primary, Bagby, Stacey M., primary, Messersmith, Wells A., primary, Karam, Sana D., primary, Dinarello, Charles A., primary, Pitts, Todd M., primary, and Marchetti, Carlo, primary

Published
2023
Full Text
View/download PDF

19. Abstract 5526: Serum proteomic scores for understanding response and mechanisms of resistance to immune checkpoint inhibitors in non-small cell lung cancer

Author

Davis, Andrew A., primary, Park, Jonghanne, additional, Iams, Wade T., additional, Oh, Michael S., additional, Lentz, Robert W., additional, Roder, Heinrich, additional, Roder, Joanna, additional, Asmellash, Senait, additional, Net, Lelia, additional, Grigorieva, Julia, additional, Mohindra, Nisha, additional, Villaflor, Victoria, additional, and Chae, Young Kwang, additional

Published
2020
Full Text
View/download PDF

20. Abstract 5527: Serum proteomic scores for understanding the mechanisms of immune-related adverse events (irAEs) in non-small cell lung cancer

Author

Davis, Andrew A., primary, Park, Jonghanne, additional, Kim, Leeseul, additional, Gim, Gahyun, additional, Iams, Wade T., additional, Oh, Michael S., additional, Lentz, Robert W., additional, Roder, Heinrich, additional, Roder, Joanna, additional, Asmellash, Senait, additional, Net, Lelia, additional, Grigorieva, Julia, additional, Mohindra, Nisha, additional, Villaflor, Victoria, additional, and Chae, Young Kwang, additional

Published
2020
Full Text
View/download PDF

21. Early Assessment of Molecular Progression and Response by Whole-genome Circulating Tumor DNA in Advanced Solid Tumors

Author

Davis, Andrew A., primary, Iams, Wade T., additional, Chan, David, additional, Oh, Michael S., additional, Lentz, Robert W., additional, Peterman, Neil, additional, Robertson, Alex, additional, Shah, Abhik, additional, Srivas, Rohith, additional, Wilson, Timothy J., additional, Lambert, Nicole J., additional, George, Peter S., additional, Wong, Becky, additional, Wood, Haleigh W., additional, Close, Jason C., additional, Tezcan, Ayse, additional, Nesmith, Ken, additional, Tezcan, Haluk, additional, and Chae, Young Kwang, additional

Published
2020
Full Text
View/download PDF

22. Abstract P5-01-13: Longitudinal changes in whole-genome (WG) cell-free DNA (cfDNA) and methylation as a blood-based biomarker to identify early disease progression in advanced breast cancer

Author

Davis, Andrew A, primary, Chan, David, additional, Oh, Michael S, additional, Lentz, Robert W, additional, Peterman, Neil, additional, Robertson, Alex, additional, Srivas, Rohith, additional, Shah, Abhik, additional, Lambert, Nicole, additional, Tezcan, Ayse, additional, Tezcan, Haluk, additional, and Chae, Young Kwang, additional

Published
2020
Full Text
View/download PDF

23. Early assessment of molecular progression and response by whole-genome circulating tumor DNA in advanced solid tumors

Author

Davis, Andrew A., primary, Iams, Wade T., additional, Chan, David, additional, Oh, Michael S., additional, Lentz, Robert W., additional, Peterman, Neil, additional, Robertson, Alex, additional, Shah, Abhik, additional, Srivas, Rohith, additional, Wilson, Timothy, additional, Lambert, Nicole, additional, George, Peter, additional, Wong, Becky, additional, Wood, Haleigh, additional, Close, Jason, additional, Tezcan, Ayse, additional, Nesmith, Ken, additional, Tezcan, Haluk, additional, and Chae, Young Kwang, additional

Published
2019
Full Text
View/download PDF

24. Abstract 2279: Serial changes in tumor-derived whole-genome cfDNA fraction to identify early disease progression prior to imaging

Author

Davis, Andrew A., primary, Iams, Wade T., additional, Chan, David, additional, Oh, Michael S., additional, Lentz, Robert W., additional, Peterman, Neil, additional, Robertson, Alex, additional, Shah, Abhik, additional, Srivas, Rohith, additional, Lambert, Nicole, additional, Wilson, Tim, additional, George, Peter, additional, Wong, Becky, additional, Tezcan, Ayse, additional, Yalamanchili, Ram, additional, Nesmith, Ken, additional, Spinosa, John C., additional, Tezcan, Haluk, additional, and Chae, Young Kwang, additional

Published
2019
Full Text
View/download PDF

27. A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer.

Author

Lentz RW, Friedrich TJ, Blatchford PJ, Jordan KR, Pitts TM, Robinson HR, Davis SL, Kim SS, Leal AD, Lee MR, Waring MRN, Martin AC, Dominguez ATA, Bagby SM, Hartman SJ, Eckhardt SG, Messersmith WA, and Lieu CH

Subjects
Humans, Male, Female, Middle Aged, Aged, Adult, Drug Resistance, Neoplasm genetics, Microsatellite Repeats, Treatment Outcome, Bevacizumab administration & dosage, Bevacizumab therapeutic use, Bevacizumab adverse effects, Colorectal Neoplasms drug therapy, Colorectal Neoplasms genetics, Colorectal Neoplasms pathology, Colorectal Neoplasms mortality, Antibodies, Monoclonal, Humanized administration & dosage, Antibodies, Monoclonal, Humanized adverse effects, Benzimidazoles administration & dosage, Benzimidazoles therapeutic use, Benzimidazoles adverse effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects
Abstract

Purpose: In this single-institution phase II investigator-initiated study, we assessed the ability of MAPK and VEGF pathway blockade to overcome resistance to immunotherapy in microsatellite-stable metastatic colorectal cancer (MSS mCRC)., Patients and Methods: Patients with MSS, BRAF wild-type mCRC who progressed on ≥2 prior lines of therapy received pembrolizumab, binimetinib, and bevacizumab until disease progression or unacceptable toxicity. After a safety run-in, patients were randomized to a 7-day run-in of binimetinib or simultaneous initiation of all study drugs, to explore whether MEK inhibition may increase tumor immunogenicity. The primary endpoint was objective response rate (ORR) in all patients combined (by Response Evaluation Criteria in Solid Tumors v1.1)., Results: Fifty patients received study drug treatment; 54% were male with a median age of 55 years (range, 31-79). The primary endpoint, ORR, was 12.0% [95% confidence interval (CI) 4.5%-24.3%], which was not statistically different than the historical control data of 5% (P = 0.038, exceeding prespecified threshold of 0.025). The disease control rate was 70.0% (95% CI, 55.4%-82.1%), the median progression-free survival 5.9 months (95% CI, 4.2-8.7 months), and the median overall survival 9.3 months (95% CI, 6.7-12.2 months). No difference in efficacy was observed between the randomized cohorts. Grade 3 and 4 adverse events were observed in 56% and 8% of patients, respectively; the most common were rash (12%) and increased aspartate aminotransferase (12%)., Conclusions: Pembrolizumab, binimetinib, and bevacizumab failed to meet its primary endpoint of higher ORR compared with historical control data, demonstrated a high disease control rate, and demonstrated acceptable tolerability in refractory MSS mCRC., (©2024 The Authors; Published by the American Association for Cancer Research.)

Published
2024
Full Text
View/download PDF

28. Nanorod dissolution quenched in the aggregated state.

Author

Rubasinghege G, Lentz RW, Park H, Scherer MM, and Grassian VH

Abstract

Metal-containing nanorods are of great interest from a number of technological perspectives, and they are also present in the natural environment. Here we show that dissolution, both rate and extent, is greater for rod-shaped alpha-FeOOH particles on the nanoscale at pH 2 relative to microrods. However, when nanorods aggregate, either at lower pH and/or high ionic strength, dissolution is either completely quenched or severely quenched, by orders of magnitude. Furthermore, nanorod suspensions are less stable compared to microrod suspensions, resulting in nanorod aggregation under conditions where microrods stay fairly well dispersed. Although recent evidence suggests that particle size is a controlling factor in the solubility of iron oxides, a fundamental understanding of the influence of particle size is just beginning to emerge. The results presented here not only address some of the complexities of size-dependent dissolution of metal-containing nanorods in solution, they also contribute to our understanding of the factors that can influence Fe-mobilization in the global environment.

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results